Highlights of weekly biotech stock moves

BTG plc (LSE:BGC) gained 4.90p to 248.4p last week after FDA approved an NDA from Centocor Ortho Biotech Inc. for Zytiga abiraterone acetate in combination with prednisone to treat metastatic, castration-resistant prostate cancer (CRPC) in patients who have been treated with docetaxel. Centocor is a subsidiary of Johnson & Johnson (NYSE:JNJ), which gained the program through its 2009 acquisition of Cougar Biotechnology Inc. Cougar received rights to abiraterone from BTG, which is eligible for milestones and royalties.

CRPC play Medivation Inc. (NASDAQ:MDVN) was up $1.69 to $24.70 last week. The company's MDV3100, which is partnered with Astellas Pharma Inc. (Tokyo:4503), is in Phase III testing...